The drug maker anticipates that the FDA will provide final approval within six months to market the drug for the treatment of patients with hypertension (i.e., high blood pressure) within the U.S.
The long-acting, selective beta blocker is currently being utilized in 50 other countries, according to Forest Laboratories.
According to the chairman and CEO of Forest Laboratories, Howard Solomon, "We expect that Nebivolol will provide an important new option for physicians in the management of hypertension."
Several clinical trials have been performed in the U.S. regarding the treatment of Nebivolol for hypertension that have shown favorable results.
